Dispatches from AAPS 2014

GSK ‘moves best people’ to keep Ebola vaccine manufacture in-house

Ebola response training at the Military Medical Center in San Antonio, Texas. (Picture: Army Medicine)

GSK is keeping its Ebola vaccine production in-house, despite previously leaked documents which suggested the company could not ramp up volume of BS-2 manufacturing without impacting its other vaccine lines.

The Director of BARDA, the US Biomedical Advanced Research and Development Authority, told the annual meeting of the American Association of Pharmaceutical Scientists this week that despite GSK plans to massively escalate production of its cAd3 EBOV vaccine candidate to millions of doses by next year, the company will not turn to a CMO.

Scale-up to commercial capacity is a daunting task for all companies producing Ebola vaccine candidates, as they try to truncate a process that normally takes two years to a projected nine to twelve months.

Added to the usual efficacy and safety hurdles, drugmakers must also deal with the simple problem of how to free up desperately-needed manufacturing capacity to reach production quotas.

For its primate studies, GSK worked with the research centre at its daughter company Okairos to produce its Ebola vaccine candidate in runs of tens of thousands of doses.

But now the company is thinking in terms of millions.

GSK made a decision to move their resources and people to take it in-house,” said BARDA’s Director Robin Robinson, whose organisation is working closely with the company.  

They reassigned their very best vaccine people – from upstream processing, downstream processing, formulation, lyophilisation, and clinical, to focus on this problem.

The company decided to move its large-scale Ebola vaccine production to its Rixensart facility, vaccine base in Belgium. The decision obviated the need to waste resources performing tech transfer to an outsourcing partner, said Robinson.


But not all vaccine makers have GSK’s capabilities – Newlink Genetics has turned to a German CMO to scale up its rVSVΔG EBOV candidate, and is “also looking at an American manufacturer,” according to Robinson.

So the resources needed to make millions of doses are being brought to bear already but it’s not an overnight process.

BARDA is funding process scale-up for the four most advanced Ebola vaccine makers – GSK, Newlink, J&J, and Profectus.

In documents leaked two weeks ago, GSK expressed concern about the “critical issue” of fill capacity and suggested regulators allow it to make cAd3 EBOV under Biosafety Level 1, instead of more stringent Level 2 conditions.

Related News

University of Texas has spent seven years developing a nasal spray vaccine against Ebola

Ebola nasal vaccine under threat as funding runs dry

Rosetta's Philae lander successfully made the first controlled touchdown on a comet nucleus, specifically Comet 67P, on November 12

'In space, no one can hear you sneeze,' say mythbusting virologists

A photo of the fraudulent product

US FDA calls out two companies over fake Ebola treatments

Phase I trials of the vaccine are ongoing.

Merck to manufacture NewLink Ebola vaccine in-house

An Ebola response worker in Sierra Leone. (Picture: European Commission DG ECHO)

US politicians plan fast-track vouchers to reward Ebola R&D

A 39-year-old woman receives a dose of the GSK Ebola vaccine candidate at the NIH Clinical Center in Bethesda, Maryland. (Image: NIAID)

Phase I success for GSK Ebola vaccine in sped-up trial

Ebola screening at Conakry Airport. The WHO has recommended exit screening at airports and land-border crossings in countries affected by Ebola

Tracking Ebola difficult in countries where war has stunted healthcare development

Immunity from legal action will help all three major vaccine manufacturers

US government offers legal immunity to Ebola vaccine manufacturers, CMOs

Kymab is using its technology to discover an Ebola mAb

Kymab in consortium to develop Ebola drug using mouse mAb tech platform

BioPharma-Reporter.com competition winner announced

BioPharma-Reporter.com competition winner announced

GSK further commits to focusing on vaccine development with the purchase

GSK invests further in vaccines with $190m buy of GlycoVaxyn

Hemispherx plant in New Brunswick New Jersey set for pre approval inspection this year

Production of wart drug with anti Ebola potential set to restart in New Jersey

Image: iStock/Golden_Brown

$62m injection in Hungary is latest boost for GSK vaccine production

GSK and guests at the groundbreaking ceremony for the vaccine production plant at the MARS Campu., Image c/o GSK

GSK breaks ground on $175m German Bexsero vaccine facility

Image: iStock/BaMiNi

Breaking the Big Four: vaccine oligopoly unlikely to be challenged, analyst

Image: iStock/fotojog

Consolidated vaccine sector urgently needs a workforce booster shot, Sanofi

The crab-eating macaque (Macaca fascicularis) also known as the cynomolgus monkey protected by Immunovaccine's Ebola vaccine

GSK and Immunovaccine: delivery techs promise to deliver Ebola vaccine

ZMapp is produced with tobacco-plant based mAbs. (Picture: Kevin Bercaw)

CMO Kentucky Bioprocessing grows Ebola mAb from tobacco

The Lausanne University Hospital ('CHUV') in Lausanne

Swissmedic OKs trial of GSK's adenovirus-based Ebola vaccine

WHO accuses pharma of ignoring diseases prevalent in poorer nations, such as Ebola

WHO slams pharma for failing to invest in 'non-profitable' Ebola R&D